公司資料
Biogen 股價、新聞與催化劑
- 股票代碼:
- BIIB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
222.82 USD (-1.35%)
收盤價
最後更新: 2026年10月1日
27.9B USD
市值
股價為何變動
最新監測到的公司動態為「Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Thera…」。相應的收盤價反應尚未產生。
公司概覽
業務概覽
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
所在地與產業分類
Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.
商業模式特徵
The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.
生技產業定位
Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.
未來催化劑
- Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。